Oculis Holding AG (OCS) carries a Roarable Rating of D (Sell) with 47/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-03, Oculis Holding AG (NASDAQ: OCS) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 47/100 at a spot price of $8.26 (+0.24% 1D, market cap $508.7M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, OCS ranks #308 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), OCS carries a Roarable D (47/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, GYRE (Gyre Therapeutics Inc.) holds a D- grade (43/100 RQD, P/E 72.3x, ROIC 25.4%, cap $507.9M) and CTMX (CytomX Therapeutics Inc.) posts a E grade (14/100 RQD, P/E N/A, ROIC -20.5%, cap $509.9M). Among the 5-stock peer group, GYRE leads on earnings multiple (72.3x) while GYRE leads on capital efficiency (25.4% ROIC).
For Oculis Holding AG (OCS), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity and sector rank #308 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9
SEC XBRL Trailing 12 Months: 0.4% FCF Margin ($14.2M FCF) & 52% Gross Margin
Put hedging (50% put share) caps near-term gamma upside (-15 pts vs max)
While OCS currently carries a cautious 47/100 (D) rating due to Whale & Options Positioning (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($9.55) and Max Pain ($8.67) forces dealer call-delta covering toward $36.19.
Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Oculis Holding AG (OCS) advanced +0.24% to $8.26, trading at 4% of its 52-week range ($7.11 – $34.47). Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.
Björn Tackenberg, M.D. Ph.D. FEAN FAAN, Professor of Neurology, will lead Oculis’ global integrated scientific strategy supporting the advancement of Privosegtor and its expansion into new therapeutic applications Aaron
Positive Phase 2 ACUITY trial findings support Privosegtor’s potential to deliver a first-in-class neuroprotective treatment for patients with optic neuritis and beyondZUG, Switzerland, October 29th, 2026 -- Oculis Holdi
HC Wainwright & Co. analyst Yi Chen reiterates Oculis Holding (NASDAQ:OCS) with a Buy and maintains $39 price target.
Privosegtor reduced post-onset increases in plasma neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) compared with placebo Lower NfL and GFAP levels provide objective, complementary biological ev
Privosegtor reduced post-onset increases in plasma neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) compared with placebo Lower NfL and GFAP levels provide objective, complementary biological ev
Privosegtor reduced post-onset increases in plasma neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) compared with placeboLower NfL and GFAP levels provide objective, complementary biological
Presentation highlights new translational data evaluating plasma NfL and GFAP as biomarkers of neuroaxonal injury and neuroinflammation ZUG, Switzerland, October 20, 2026 -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“
High-Responder Target Enrichment: 2/3 of the 176 enrolled patients carry the target TNFR1 genetic variant previously linked to enhanced clinical response in Phase 2 trials Precision Medicine Approach in a Large Market: L
Markviss innritun sjúklinga með auknar líkur á meðferðarsvörun: 2/3 af þeim 176 sjúklingum sem innritaðir voru bera þann TNFR1-erfðabreytileika sem tengdur hefur verið aukinni klínískri svörun í fasa 2 rannsóknum. Nákvæm
High-Responder Target Enrichment: 2/3 of the 176 enrolled patients carry the target TNFR1 genetic variant previously linked to enhanced clinical response in Phase 2 trialsPrecision Medicine Approach in a Large
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on OCS today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for OCS. Explore sector supply chains on /butterfly.
Across 1015 tracked Health Care securities in the Roarable RQD universe, Oculis Holding AG (OCS) ranks #308 by composite RQD confidence (47/100, grade D) and #437 by equity capitalization ($508.7M). Within this direct 5-issuer industry benchmark cohort, GYRE leads on earnings valuation at 72.3x trailing P/E, while GYRE leads on capital efficiency and profitability with 25.4% ROIC and 95.4% gross margin. OCS currently leads its immediate peer cohort in composite quantitative strength at 47/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| OCS
ACTIVE
Oculis Holding AG | D | 47/100 | — | — | — | +0.24% | $508.7M | Benchmark Subject |
| GYRE Gyre Therapeutics Inc. | D- | 43/100 | 72.3x | 95.4% | 25.4% | -28.94% | $507.9M | /gyre-vs-ocs → |
| CTMX CytomX Therapeutics Inc. | E | 14/100 | — | — | -20.5% | +2.18% | $509.9M | /ctmx-vs-ocs → |
| ARVN Arvinas Inc. | E | 22/100 | — | — | -32.1% | -0.51% | $513.9M | /arvn-vs-ocs → |
| CBIO Crescent Biopharma Inc. | E | 29/100 | — | — | -35.0% | -4.19% | $500.7M | /cbio-vs-ocs → |
Oculis Holding AG (OCS) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $508.7M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.
As of 2026-11-03, Oculis Holding AG (NASDAQ: OCS) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 47/100 at a spot price of $8.26 (+0.24% 1D, market cap $508.7M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, OCS ranks #308 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), OCS carries a Roarable D (47/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, GYRE (Gyre Therapeutics Inc.) holds a D- grade (43/100 RQD, P/E 72.3x, ROIC 25.4%, cap $507.9M) and CTMX (CytomX Therapeutics Inc.) posts a E grade (14/100 RQD, P/E N/A, ROIC -20.5%, cap $509.9M). Among the 5-stock peer group, GYRE leads on earnings multiple (72.3x) while GYRE leads on capital efficiency (25.4% ROIC).
For Oculis Holding AG (OCS), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity and sector rank #308 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.
OCS last traded at $8.26 (+0.24% on volume of 309,711 shares), positioning the stock -13.51% below its 50-day simple moving average ($9.55) and -55.73% below its 200-day simple moving average ($18.66). Across its 52-week range of $7.11 to $34.47, OCS sits at the 4.2% percentile with a 14-day RSI of 45.7 (NEUTRAL RANGE) and an implied next-earnings move of ±11.9% ($7.28 to $9.24).
Oculis Holding AG (OCS) earns a live Roarable RQD composite score of 47/100, corresponding to a D letter grade (Roarable Sell) at a spot price of $8.26 (+0.24% 1D, market capitalization $508.7M).
Oculis Holding AG (OCS) is listed on NASDAQ and classified under the Health Care sector, in the Biotechnology: Pharmaceutical Preparations industry. The profile lists a market capitalization of $0.5B.
No upstream or downstream dependencies, sector correlations, or bottlenecks are identified in the source data. Sector classification is Health Care and industry is Biotechnology: Pharmaceutical Preparations. Beyond this classification, no ripple effects can be drawn from the source.
Real-time company headlines, analyst actions, and sector developments for Oculis Holding AG (OCS) • Click "Debate This Headline" to argue it in the Roar Pit below
Björn Tackenberg, M.D. Ph.D. FEAN FAAN, Professor of Neurology, will lead Oculis’ global integrated scientific strategy supporting the advancement of Privosegtor and its expansion into new therapeutic applications Aaron
Positive Phase 2 ACUITY trial findings support Privosegtor’s potential to deliver a first-in-class neuroprotective treatment for patients with optic neuritis and beyondZUG, Switzerland, October 29th, 2026 -- Oculis Holdi
HC Wainwright & Co. analyst Yi Chen reiterates Oculis Holding (NASDAQ:OCS) with a Buy and maintains $39 price target.
Privosegtor reduced post-onset increases in plasma neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) compared with placebo Lower NfL and GFAP levels provide objective, complementary biological ev
Privosegtor reduced post-onset increases in plasma neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) compared with placebo Lower NfL and GFAP levels provide objective, complementary biological ev
Privosegtor reduced post-onset increases in plasma neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) compared with placeboLower NfL and GFAP levels provide objective, complementary biological
Presentation highlights new translational data evaluating plasma NfL and GFAP as biomarkers of neuroaxonal injury and neuroinflammation ZUG, Switzerland, October 20, 2026 -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“
High-Responder Target Enrichment: 2/3 of the 176 enrolled patients carry the target TNFR1 genetic variant previously linked to enhanced clinical response in Phase 2 trials Precision Medicine Approach in a Large Market: L
Here is why I am bullish on OCS here at $8.26: The balance sheet metrics (Altman Z 2.5, Piotroski F 6/9, Debt/Equity 0.5) are the strongest pillar at 13/20.. Compare OCS's 0.0% operating margin and 0.0% ROIC against the rest of Biotechnology: Pharmaceutical Preparations. As long as cash conversion holds up, dips toward $7.85 are getting bought.
@DeltaGamma_99 Agree on the RQD 47/100 quality, though with 1.0 beta I'm scaling in with half-size at $8.26 and keeping dry powder in case we test $7.68.
Careful chasing OCS at $8.26. Zero ROIC and zero FCF yield, combined with a 5/20 whale flow score and a D-grade distribution warning, show weak cash returns and institutional selling pressure.. Gross margin is 0.0%, but operating margin is 0.0%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $6.61 on multiple compression.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Gideon Ashmere, Ellis Vennor, Tessa Rookmere, Soren Halewick, Iona Brackenford, Nadia Vellacrest, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your email address below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).